According to Google DeepMind on Twitter, the company has made the AlphaGenome model and its weights publicly available to scientists worldwide, aiming to accelerate advancements in genomics research. This release provides researchers with direct access to cutting-edge AI technology for genomic analysis, fostering collaborative innovation and expanding business opportunities in biotechnology and healthcare applications. As reported by Google DeepMind, this move is expected to speed up the discovery of genetic insights and practical applications in precision medicine.

According to Google DeepMind, their C2S-Scale 27B artificial intelligence model, developed on the open-source Gemma family, has identified a new potential pathway for cancer therapy by detecting cancer cells that evade the immune system (source: @GoogleDeepMind). This discovery, validated in collaboration with Yale University scientists, demonstrates how advanced AI can accelerate breakthrough drug discovery and oncology research. The practical application of C2S-Scale 27B highlights the growing role of open AI models in uncovering non-obvious therapeutic targets, offering pharmaceutical companies and biotech startups new business opportunities in precision medicine and immunotherapy.

According to Demis Hassabis on Twitter, DeepMind has launched AlphaGenome, a new AI-powered DNA sequence model now accessible through the AlphaGenome API. This model enables researchers to predict genome function with high accuracy, accelerating biological discovery and facilitating the development of innovative treatments. The integration of AlphaGenome into scientific workflows is expected to enhance genomics-driven drug discovery, streamline disease research, and create new business opportunities in AI-powered healthcare and precision medicine (source: @demishassabis, June 25, 2025).